Table 2.

Base editing enrichment strategies

Strategy	Cells	Target locus	Selection	Editing pre-enrichment	Editing post-enrichment	Fold increase	Ref.
BE-FLARE	PC9	BRAF (T57I)	FACS (BFP to GFP)	9%	55%	6.1-fold	[176]
BE-FLARE	PC9	BRAF (Q58*)	FACS (BFP to GFP)	4%	20%	5-fold	[176]
BE-FLARE	PC9	EGFR (T790)	FACS (BFP to GFP)	1%	18%	18-fold	[176]
TREE	HEK293T	APOE (R158C)	FACS (BFP to GFP)	9%	26%	2.9-fold	[177]
TREE	hPSCs	APOE (R158C)	FACS (BFP to GFP)	6%	23%	3.8-fold	[177]
BIG-TREE	hPSCs	APOE (R158C)	FACS (BFP to GFP)	10%	80–90%	> 8-fold	[178]
GO	DLD1	EMX1/FANCF/CTNNB1	Antibiotic resistance	< 1%	~ 30–60%	10- to 120-fold	[171]
GO	Pancreatic organoid	Intergenic region Chr8/APC	Antibiotic resistance	< 1%	44%	> 44-fold	[171]
Universal toxin-based selection	HEK293T	DPM2/EGFR/EMX1/PCSK9/ DNMT3B	Drug selection	N.A	N.A	4 to 7-fold	[120]
Universal toxin-based selection	HEK293T	EMX1/CTLA4/IL2RA/ AAVS1	Drug selection	N.A	N.A	6 to 13-fold	[120]
Universal toxin-based selection	HCT116	PCSK9	Drug selection	N.A	N.A	13-fold	[120]
ACE	HEK293T	FANCF	FACS	0.2% 15%	58% 78%	290-fold and 5.2-fold	[175]
BEAR	HEK293T	HEK/CCR5/FANCF/SCN5a	FACS	3–10%	20–25%	2.8 to 4.8-fold	[179]
BEAR	HEK293T	HEK/CCR5/FANCF/SCN5a	FACS	5–40%	12–60%	1.3 to 2.9-fold	[179]
BEON	HEK293T	Human site 1 (S1)	FACS	9.5% ± 4.9%	70.6% ± 7.3%	2.4-fold	[172]
BEON	HEK293T	CAR	FACS	N.A	37.54% (± 1.27%)	NA	[172]
BEON	Neuro2A	mTmem5	FACS	N.A	~ 60%	NA	[172]

N.A. not available